Brief: Briacell Partners With New York Cancer & Blood Specialists For Pivotal Phase 3 Study Of Bria-IMT In Advanced Breast Cancer
04/10/2023 14:03
Oct 4 (Reuters) - Briacell Therapeutics Corp BCT.TO :
* BRIACELL PARTNERS WITH NEW YORK CANCER & BLOOD SPECIALISTS
(NYCBS) FOR PIVOTAL PHASE 3 STUDY OF BRIA-IMT™ IN ADVANCED
BREAST CANCER
Source text for Eikon: ID:nGNXFtRn9
Further company coverage: BCT.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Briacell Therapeutics
See all newsBrief: Briacell Therapeutics Prices 1.45 Million Common Shares At $3.25 Per Share
Brief: Briacell Receives Positive Recommendation From Data Safety Monitoring Board (Dsmb) For Phase 3 Study In Metastatic Breast Cancer
Brief: Briacell Expands Pipeline To Include An Ovarian Cancer Immunotherapy Candidate, Bria-Ova+™
Brief: Briacell Phase 3 Bria-Imt™ Study Enrollment Surpasses 230 Patients
Brief: Briacell Adds Nyu Langone Health’S Perlmutter Cancer Center As Clinical Site In Pivotal Phase 3 Breast Cancer Study